Aspartate amino transferase (AST or SGOT) and alanine amino transferase (ALT or SGPT) ? 1.5 × institutional ULN.
Aspartate amino transferase (AST) or alanine amino transferase (ALT) > 2.5 times the upper limit of normal (ULN).
Alanine amino transferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN (may not have abnormalities in both bilirubin and transaminases)
Obtained =< 21 days prior to registration: Alanine amino transferase (ALT) < 2.5 X ULN, with normal bilirubin; NOTE: Concomitant elevations in bilirubin and ALT above 1.5 x ULN (upper limit of normal) is not permitted
Within 3 weeks prior to study registration: \r\nAlanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) within 3 weeks prior to study registration
Aspartate amino transferase (AST) or Alanine amino transferase (ALT) >3 times ULN in patient without liver metastasis or liver cirrhosis
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer or stent placement)
Aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate amino transferase (AST or serum glutamic oxaloacetic transaminase [SGOT]) and alanine amino transferase (ALT or serum glutamate pyruvate transaminase [SGPT]) =< 2.0 x institutional ULN
Aspartate amino transferase (AST) or alanine amino transferase (ALT) =< three times the upper limit of (institutional/central) normal (ULN) (if related to liver metastases =< five times ULN)
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate amino transferase (AST) or alanine amino transferase (ALT) >= 2.5 times the upper limit of normal (if related to liver metastases >= five times the upper limit of normal)
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ? 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior to randomization)
Alanine amino transferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (tested within 14 days prior to registration)\r\n* Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
Alanine amino transferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (upper limit of normal); concomitant elevations in AST/ALT above 1.0 x ULN are not permitted
Serum aspartate aminotransferase and alanine amino-transferase of at least 5 times the upper limit of normal
Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (ULN), or AST or ALT greater than 5 times the ULN for those with Gilbert syndrome.
Aspartate amino transferase (AST) or alanine amino transferase (ALT) >= three (3) times the upper limit of normal
Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the ULRR in the presence of liver metastases.
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Total bilirubin =< 1.5 X ULN (evaluated within 28 days of randomization); concomitant elevations in bilirubin and aspartate amino transferase (AST)/alanine aminotransferase (ALT) above 1.0 x ULN are not permitted